Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).

Trial Details

NCT ID
NCT07259317
Phase
PHASE2
Sponsor
Corcept Therapeutics
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • Relacorilant
  • Nab-paclitaxel
  • Gemcitabine
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Los Angeles, California, United States|34.05223,-118.24368
  • Orange, California, United States|33.78779,-117.85311
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Goshen, Indiana, United States|41.58227,-85.83444

Key Eligibility Criteria

  • Signed and dated informed consent form prior to screening procedures
  • Histologic diagnosis or cytologic diagnosis of pancreatic adenocarcinoma (PDAC)
  • Initial diagnosis of metastatic disease occurred ≤9 weeks prior to enrollment in the study
  • Life expectancy of ≥3 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →